

REF



AU242025

50

Intended Use

Aurora Carbohydrate Antigen 19-9 Assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of Carbohydrate Antigen 19-9 (CA19-9) in human serum and plasma. The assay kit is intended for in vitro diagnostic use.

Summary

Carbohydrate Antigen 19-9 (CA19-9) also known as sialyl-LewisA, is a tetrasaccharide which is usually attached to O-glycans on the surface of cells. It synthesized and secreted by normal human pancreatic cells, biliary ductular cells, gastric epithelial cells, colon epithelial cells, endometrial cells and salivary gland epithelial cells. Elevated CA19-9 levels usually associated with colorectal carcinoma (30%), pancreatic tumors (80%), hepatobiliary tumors (67%), stomach cancers (40 to 50%), hepatocellular carcinoma (30 to 50%), breast cancer (15%). In addition, it has been reported that elevated CA19-9 levels can be found in other non-malignant conditions such as pulmonary and thyroidal diseases, diabetes mellitus, and gynecologic disease. CA19-9 is an important indicator for diagnosis and response to treatment and the surveillance of pancreatic or hepatobiliary cancers.

Test Principle

The Aurora CA19-9 assay is a quantitative sandwich immunoassay to determine the presence of CA19-9 in human serum and plasma using CMIA technology with flexible assay protocols.

1. Sample, paramagnetic anti-CA19-9 coated microparticles and a conjugate containing acridinium-labeled anti-CA19-9 are mixed, CA19-9 present in the sample binds to anti-CA19-9 coated microparticles and acridinium-labeled anti-CA19-9, forming an antigen antibody complex.
2. After further incubation and washing, Pre-Trigger and Trigger Solutions are added to the reaction mixture.
3. The resulting chemiluminescent reaction is

measured as relative light units (RLUs). There is a relationship between the amount of CA19-9 in the sample and the RLUs detected by the optical system. Results are calculated automatically based on the previously established calibration curve.

Reagents

- | | |
|------------|---------------------------------------|
| R1 | 3.0 mL |
| R2 | 3.0 mL |
| CAL | Contains 3 levels, 1.0 mL each level. |
| CON | Contains 2 levels, 1.0 mL each level |
- R1:** Microparticles. Anti-CA19-9 coated microparticles.
Preservative: 0.05% ProClin 300
- R2:** Conjugate. Acridinium-labeled anti-CA19-9.
Preservative: 0.05% ProClin 300
- CAL:** Calibrator. Solutions of different concentrations of CA19-9. Preservative: 0.05% ProClin 300
- CON:** Control. Tris buffer solution for quality control of Carbohydrate Antigen 19-9 (CA19-9)

Required Materials

- Pre-Trigger Solution: Hydrogen peroxide solution.
- Trigger Solution: Sodium hydroxide solution.
- Wash Buffer: Phosphate buffered saline solution with 0.05% ProClin 300.

Safety Precautions

- Exercise the normal precautions required for handling all laboratory reagents.
- Disposal of all waste material should be in accordance with local guidelines.
- Wear gloves when handling specimens or reagents.
- Clean and disinfect all spills of specimens or reagents using a suitable disinfectant.
- Trigger solution contains sodium hydroxide (NaOH) and should be avoided contact with eyes.

Warning (Contains Proclin 300)

Hazardous Component: 0.05% Proclin 300

- Reaction mass of:
5-chloro-2-methyl-4-isothiazolin [EC no. 247-500-7]
and 2-methyl-4-isothiazolin-3-one [EC no.
200-239-6] (3:1)

Hazard Statement

- H317: May cause an allergic skin reaction.
- H319: Causes serious eye irritation.
- H410: Very toxic to aquatic life with long-lasting effects.

Precautionary Statement

- P261: Avoid breathing dust/fume/gas/mist/vapors/spray.
- P264: Wash hands thoroughly after handling.
- P272: Contaminated work clothing should not be allowed out of the workplace.
- P280: Wear protective gloves/protective clothing/eye protection/face protection.
- P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- P337+P313: If eye irritation persists: Get medical advice/attention.
- P333+P313: If skin irritation or rash occurs: Get medical advice/attention.
- P302+P352: IF ON SKIN: Wash with plenty of soap and water.
- P321: Seek immediate care from a doctor.
- P363: Wash contaminated clothing before reuse.
- P273: Avoid release to the environment.
- P391: Collect spillage.
- P501: Dispose of contents/container in a safe way.

Reagent Handling

- Do not use reagent kits beyond the expiration date.
- Do not pool reagents within a kit or between kits.
- Before loading the reagent kit on the system for the first time, the microparticle bottle requires mixing to resuspend microparticles that may have settled during shipment.
- Septums MUST be used to prevent reagent evaporation and contamination and to ensure reagent integrity. Reliability of assay results cannot be guaranteed if septums are not used according to the instructions in this package insert.
- To avoid contamination, wear clean gloves when

placing a septum on an uncapped reagent bottle.

- Once a septum has been placed on an open reagent bottle, do not invert the bottle as this will result in reagent leakage and may compromise assay results.

Reagent Storage

REAGENT	Storage Temperature	Maximum Storage Time
Unopened	2°C~8°C Do not freeze.	12 months
On board/ Opened	2°C~8°C Do not freeze.	28 days

- Reagents may be stored on or off the chemiluminescence immunoassay analyzer. If reagents are removed from the analyzer, store them at 2-8°C (with septums and replacement caps) in an upright position. For reagents stored off the system, it is recommended that they be stored in their original trays and boxes to ensure they remain upright. If the microparticle bottle does not remain upright (with a septum installed) while in refrigerated storage off the system, the reagent kit must be discarded.

Calibrator & Control Storage

CAL	CON	Storage Temperature	Maximum Storage Time
Unopened		2°C~8°C	12 months
Opened		2°C~8°C	30 days

Applicable Analyzer

Automatic Chemiluminescence Immunoassay Analyzer (model: Aurora S-01 System).

Specimen Types

Verified specimen types to be used with this assay:

Specimen Types	Collection Tubes
Serum	Serum separator tubes (SST)
Plasma	Dipotassium EDTA Tripotassium EDTA Sodium heparin Lithium heparin powder Plasma separator tubes (PST) -lithium heparin gel

- Other specimen collection tube types have not been tested with this assay.

- Liquid anticoagulants may have a dilution effect resulting in lower concentrations for individual patient specimens.
- The instrument does not provide the capability to verify specimen type. It is the responsibility of the operator to verify that the correct specimen types are used in the assay.

Specimen Conditions

Do not use specimens with the following conditions:

- Heat-inactivated
- Pooled
- Grossly hemolyzed (> 500 mg/dl hemoglobin)
- Obvious microbial contamination
- Fungal growth
- For accurate results, serum and plasma specimens should be free of fibrin, red blood cells, and other particulate matter. Serum specimens from patients receiving anticoagulant or thrombolytic therapy may contain fibrin due to incomplete clot formation.
- To prevent cross contamination, use of disposable pipettes or pipette tips is recommended.

Preparation for Analysis

- Follow the tube manufacturer’s processing instructions for collection tubes. Gravity separation is not sufficient for specimen preparation.
- Mix thawed specimens thoroughly by low speed vortexing or by inverting 10 times. Visually inspect the specimens. If layering or stratification is observed, continue mixing until specimens are visibly homogeneous.
- Avoid more than 3 freeze/thaw cycles.
- To ensure consistency in results, specimens must be transferred to a centrifuge tube and centrifuged for a minimum of 30,000 g-minutes before testing if they contain fibrin, red blood cells, or other particulate matter, they were previously frozen.
- Examples of acceptable time and force ranges that meet this criterion are listed in the table below. Centrifugation time using alternate Relative Centrifugal Force values (RCF) can be calculated using the following formula:

Centrifugation Time (Minutes)	RCF (×g)	g × minutes
10	3,000	30,000
15	2,000	30,000
20	1,500	30,000

- Transfer clarified specimen to a sample cup or secondary tube for testing. For centrifuged specimens with a lipid layer, transfer only the clarified specimen and not the lipemic material.
- Inspect all specimens for bubbles. Remove bubbles with an applicator stick before analysis. Use a new applicator stick for each specimen to prevent cross contamination.

Specimen Storage

Specimen Type	Storage Temperature	Maximum Storage Time
Serum/Plasma	Room temperature	≤ 8 hours
	2°C~8°C	≤ 7 days
	-20°C	≤ 90 days

- Remove serum or plasma from the clot, red blood cells, or separator gel if stored longer than the maximum room temperature storage time.
- Remove serum or plasma from the clot, red blood cells, or separator gel if stored longer than the maximum 2-8°C storage time and store frozen.
- Frozen specimens must be mixed thoroughly after thawing.
- Use caution in handling patient specimens to prevent cross-contamination.
- Do not exceed the storage limitations listed above.

Assay Procedure

- Refer to the system operating instruction or the online help system for detailed information on preparing the system.
- Before loading the reagent kit on the system for the first time, the microparticle bottle requires mixing to resuspend microparticles that may have settled during shipment. After the first time the microparticles have been loaded, no further mixing is required.

- Invert the microparticle bottle 30 times. Visually inspect the bottle to ensure microparticles are resuspended. If microparticles are still adhered to the bottle, continue to invert the bottle until the microparticles have been completely resuspended. If the microparticles do not resuspend, DO NOT USE. Once the microparticles have been resuspended, place a septum on the bottle.
 - Load the reagent kit on the chemiluminescence immunoassay analyzer.
 - Verify that all necessary reagents are present.
 - Verify adequate sample volume is present prior to running the test.
 - Sample volume for first test: 250 µL
 - Sample volume for each additional test from same sample cup: 50 µL
 - The test-specific parameters stored in barcode on the reagent pack are read in. In cases the barcode cannot be read, enter the sequence numbers.
 - Order calibration, if necessary.
 - Prepare Carbohydrate Antigen 19-9 Calibrators and Controls.
 - Mix calibrator(s) and controls by gentle inversion before use.
 - Hold bottles vertically and dispense recommended volumes into each respective sample cup.
 - Place the calibrators in the calibrator rack in the sample zone.
 - Calibration.
 - Load samples. For information on loading samples, refer to the Analyzer's Operations Manual.
 - Press RUN.
 - The chemiluminescence immunoassay analyzer performs all the functions automatically and calculates the results.
- For optimal performance, it is important to perform routine maintenance as described in the Analyzer's Operations Manual. Perform maintenance more frequently when required by laboratory procedures.

Sample Dilution Procedures

- Samples with a CA19-9 value exceeding 1000 U/mL may be diluted using the Manual Dilution

Procedure.

Manual Dilution Procedure

Suggested dilution: 1:10

- Add 100 µL of the sample to 900 µL of Stroke physiological saline solution or dilutions.
- The operator must enter the dilution factor in the Patient or Control order screen. The system will use this dilution factor to automatically calculate the concentration of the sample before dilution and report the result.

Calibration

- Traceability: This assay has been standardized against the Immunoassay CA19-9 Assay kit produced at Roche.
- Every CA19-9 assay kit has a two-dimension code label containing the predefined master curve of the particular reagent lot.
- Test Calibrators in duplicate. The calibrators should be priority loaded. A replicate of each control level must be tested to evaluate the assay calibration. Ensure that assay control values are within the ranges specified in the respective control package insert.
- Once calibration is accepted and stored, all subsequent samples may be tested without further calibration unless:
 - After 28 days when using the same lot reagent.
 - A reagent kit with a new lot number is used.
 - Controls are out of range.
 - Required by pertinent regulations.
- Assay may also need to be recalibrated after specified service procedures have been performed or maintenance to critical part or subsystems that might influence the performance of the assay. For detailed information on how to perform an assay calibration, refer to the Analyzer's Operations Manual.
- Calibration Range: 0.6 U/mL ~ 1000 U/mL.

Quality Control Procedures

- Order Control, if necessary.
- The recommended control requirement for the Aurora CA19-9 assay is that a single replicate of

each control level be tested:

- Once every 24 hours or each day of use
- After performing calibration
- After instrument service procedures or maintenance that may affect assay performance have been performed.
- If the quality control procedures in your laboratory require more frequent use of controls to verify test results, follow your laboratory-specific procedures.
- Each laboratory should establish control ranges to monitor the acceptable performance of the assay. If a control is out of its specified range, the associated sample results are invalid and the samples must be retested. Recalibration may be indicated.
- These results should be applied to your laboratory's quality control practices. In addition, the laboratory must ensure that the matrix of the control material is suitable for use in the assay per the assay package insert.
- Unless specified, target values and ranges provided with the commercial control product insert are guidelines only and should not be used for quality control purposes.
- Refer to Clinical and Laboratory Standards Institute (CLSI) Document C24-A3, or other published guidelines for general quality control recommendations.

Results

Calculation

- The analyzer automatically calculates the concentration of each sample. The results are given in U/mL.

Limits

- Results should be used in conjunction with other data; e.g., symptoms, results of other tests, and clinical impressions.
- If the CA19-9 results are inconsistent with clinical evidence, additional testing is recommended.
- Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may contain human

anti-mouse antibodies (HAMA). Such specimens may show either falsely elevated or depressed values when tested with assay kits that employ mouse monoclonal antibodies. Additional information may be required for diagnosis.

- Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference, and anomalous values may be observed. Additional information may be required for diagnosis.
- Rheumatoid factor (RF) in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Additional information may be required for diagnosis.
- The Aurora Carbohydrate Antigen 19-9 assay is susceptible to interference effects from triglycerides at >1000 mg/dL.
- There is no high-dose HOOK effect at CA19-9 concentrations up to 500000 U/mL.

Expected Values

- It is recommended that each laboratory establish its own reference range, which may be unique to the population it serves depending upon geographical, season, patient, dietary, or environmental factors. A study was performed based on guidance from Clinical and Laboratory Standards Institute (CLSI) C28-A3c.
- Human serum specimens from apparently healthy individuals were collected the 172 specimens, 86 were female and 86 were male, age between 21 and 90 years.

The population	n	Reference range*
Apparently healthy individuals	172	≤ 35 U/mL

*According to the 95th percentile.

*Representative data; results in individual laboratories and in different geographical areas may vary from these data.

Specific Performance Characteristics

- Assay results obtained in individual laboratories

may vary from data presented.

Limit of Blank (LoB)

- The Limit of Blank was determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A requirements.
- The Limit of Blank is the 95th percentile value from $n \geq 20$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.
- The observed LoB value was ≤ 0.6 U/mL.

Accuracy

Intra Assay Variation

- Within run variation was determined by replicate determination ($n=10$) of two different control sera in one assay. The within assay variability is $\leq 8.0\%$.

Inter Assay Variation

- Inter assay variation was determined by replicate measurements ($n=10$) of two different control sera in 3 different lots. The inter assay variation is $\leq 10.0\%$.

Intra-Assay, n=10			Inter-Assay, n=10×3		
Sample	Mean (U/mL)	CV	Sample	Mean (U/mL)	CV
1	42.4	5.4%	1	42.7	4.8%
2	154.6	4.3%	2	158.7	5.1%

Linearity

- The linearity was determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP6-A requirements.
- The linearity range was verified by more than 6 concentration levels which encompass or be equal to the minimum and the maximum values of linearity range and duplicate assays ($n=3$) at all levels.
- The Aurora Carbohydrate Antigen 19-9 assay has been demonstrated to be linear from 1.2 U/mL to 1000 U/mL, regression ≥ 0.99 and max diff $\leq 15\%$ in this interval.

Interference

- A study was performed based on guidance from CLSI EP7-A2.
- Potentially interfering substances were evaluated to determine whether CA19-9 concentrations were affected when using the Carbohydrate Antigen 19-9 assay. Samples containing the potential interferents were prepared at two CA19-9 concentrations. The samples were assayed, and the CA19-9 concentrations of the spiked samples were compared to the reference samples.

Potential Interferent	Interferent Concentration	% Interferent Bias
Bilirubin	20 mg/dL	$\leq 10\%$
Hb	500 mg/dL	$\leq 10\%$
Intralipid	1000 mg/dL	$\leq 10\%$
Total protein	10 g/dL	$\leq 10\%$
RF	1000IU/mL	$\leq 10\%$
ANA	400AU/mL	$\leq 10\%$
HAMA	600ng/mL	$\leq 10\%$

Reference

1. Scarà S, Bottoni P, Scatena R. CA19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015; 867:247-60.
2. Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA19-9 in biliary pathology. Pancreatology. 2018 Dec;18(8):862-867.
3. Goh SK, Gold G, Christophi C, Muralidharan V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg. 2017 Dec;87(12):987-992.
4. Kim S, Park BK, Seo JH, et al. Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases. Sci Rep. 2020;10(1):8820.
5. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007 Apr;33(3):266-70.
6. Thomsen M, Skovlund E, Sorbye H, et al. Prognostic role of carcinoembryonic antigen and

carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA19-9 level and poor outcome. Br J Cancer. 2018;118(12):1609-1616.

7. Kim NH, Lee MY, Park JH, et al. Serum CEA and CA19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia. Yonsei Med J. 2017;58(5):918-924.

Contact Information



Medunion S.L.
Carrer de Tapioles 33, 2-1, 08004,
Barcelona, SPAIN.



Carbon Technologies LLC
Innovation Park Muscat (IPM), P.O. Box 92, Al
Khoudh 123, Muscat, OMAN.


















24-hour service hotline: +968-97058350

After-sale Service Center: Carbon Technologies LLC



Release Date: Date of Manufacture:

Symbols

	Manufacturer
	Date of manufacture
	Use-by date
	Contains sufficient for <n> tests
	Consult instructions for use
	Biological risks
	Temperature limit
	CE Marking
	EU Representative
	In Vitro diagnostic medical device
	Catalogue Number
	Batch code
	Reagent
	Microparticles
	Conjugate
	Calibrator
	Control